Aspect Biosystems has received substantial investment from the federal government.
The Vancouver-based biotechnology company pioneering a novel category of regenerative medicine attracted $79 million from Canada as part of a multiyear, $280M project.
The project will aim to accelerate the advancement of Aspect’s pipeline of bioengineered cellular medicines for serious metabolic and endocrine diseases, enhance the company’s clinical development capabilities, and strengthen the its vertically integrated platform, according to a statement.
“This investment from the Government of Canada is a powerful vote of confidence and adds to the significant momentum at Aspect as we advance our bioengineered cellular medicines towards patient impact,” commented Tamer Mohamed, Chief Executive Officer, Aspect Biosystems.
“With this investment and the deepening of our partnership with the Government of Canada, we are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world,” the CEO continued.
Aspect is developing a new class of modifying therapies that are designed to restore or supplement biological functions in the body and deliver functional cures to patients living difficult-to-treat diseases.
Aspect Biosystems is an “example of Canada’s leadership in scientific innovation and advanced biomanufacturing,” according to Mélanie Joly, Minister of Industry.
“By investing in the development and commercialization of cutting-edge cellular medicines, our government is helping to create high-quality jobs, drive economic growth, and position Canada as a leader in biotechnology,” she stated. “This partnership will accelerate life-changing therapies for patients, strengthen our economy, and ensure Canadian talent continues to thrive in the innovation sector.”
“We have built a truly world-class team with deep cell therapy development expertise,” Mohamed said, noting that the team “recently entered a new phase of our partnership with Novo Nordisk to develop curative medicines for diabetes, integrating key stem cell and hypoimmune cell engineering technologies under Aspect’s leadership.”
The companies say the new chapter of their collaboration builds on work underway since 2023 and reflects a shared goal of accelerating potentially curative therapies for serious metabolic diseases. Under the updated agreement, Aspect has acquired rights to Novo Nordisk’s stem cell–derived islet cell and hypoimmune cell engineering technologies and will take the lead on development, manufacturing, and commercialization.
The agreement also included an additional equity investment by Novo Nordisk in Aspect, along with continued research funding.
Leave a Reply